1/50
Vocabulary practice flashcards covering renal anatomy, glomerular filtration rate, crystalloids and colloids, acute kidney injury (AKI), acute tubular necrosis (ATN), electrolyte and acid/base imbalances, renal replacement therapies, capillary leak syndrome (third spacing), SIADH, and diabetes insipidus.
Nephron
The structural and functional unit of the kidney (approximately 1 million per kidney), consisting of the glomerulus, Bowman's capsule, proximal convoluted tubule, Loop of Henle, distal convoluted tubule, and collecting duct.
Glomerular Filtration Rate (GFR)
The rate at which filtrate (urine) is formed by the kidneys; normally 125ml/min. A rate <100ml/min indicates decreased kidney function, and <15ml/min indicates kidney failure.
Renal Autoregulation
The intrinsic mechanism by which afferent arterioles adjust their diameter (vasodilating during hypotension and vasoconstricting during hypertension) to maintain consistent renal blood flow and perfusion within a range of 60–180mmHg or a mean arterial pressure (MAP) ≥65mmHg.
Net Filtration Pressure (NFP)
The overall pressure driving fluid out of the glomerular capillaries into Bowman's capsule (10mmHg), calculated as Glomerular hydrostatic pressure (60mmHg) minus the sum of Bowman's capsule hydrostatic pressure (18mmHg) and Glomerular colloid osmotic pressure (32mmHg).

Osmolality
The measure of the number of dissolved solute particles in a solution; normal serum plasma osmolality ranges from 275 to 295mOsm/kg.
Crystalloids
Aqueous electrolyte solutions used for intravenous fluid replacement; classified based on tonicity relative to plasma as isotonic (0.9%NaCl, Lactated Ringer's), hypotonic (0.25%NaCl, 0.45%NaCl), or hypertonic (3%NaCl, D5NaCl, D5LR, D50.45%NaCl).
Colloids
High molecular weight substances (25%Albumin, Hetastarch, and blood products such as PRBC, FFP, and Platelets) that do not cross the normal capillary membrane and generate oncotic pressure to pull fluid into the intravascular space.
Free H2O Solutions
Intravenous dextrose solutions (D5W, D10, D50) that do not remain in the intravascular space once dextrose is metabolized (1L of D5W provides 50g dextrose or 170cal/L), lowering plasma osmolality and distributing water to all body compartments.
Acute Kidney Injury (AKI)
The sudden loss of renal function evidenced by an increase in blood urea nitrogen (BUN), an increase in serum creatinine, oliguria, electrolyte and acid/base disruptions, and fluid volume imbalances.
Blood Urea Nitrogen (BUN)
The end product of protein metabolism resulting from the breakdown of ammonia in the liver; normal serum value is 10–20mg/dl. It is not a solely reliable indicator of kidney damage as it is affected by protein intake, GI bleeding, cell catabolism, and fluid administration.
Serum Creatinine
The end product of protein metabolism produced by muscle and filtered by the kidneys; normal serum value is 0.7–1.4mg/dl, providing a better and more specific indicator of renal function than BUN.
Oliguria
A reduction in urine output below 400ml/day in adults; adequate urine output assessment is determined by the formula 0.5ml/kg/hr.
Prerenal AKI
Acute kidney injury caused by any condition producing renal hypoperfusion (accounting for 58% of AKI cases), such as decreased cardiac output states, hemorrhage, vasodilation from sepsis, or thrombosis.
Intrarenal AKI
Acute kidney injury resulting from direct ischemic or toxic insult to the nephron structure (accounting for 34% of AKI cases), frequently associated with urinary sediment or granular casts, rhabdomyolysis, nephrotoxic medications, or contrast dye.
Postrenal AKI
Acute kidney injury caused by mechanical obstruction hindering the flow of urine downstream from the kidneys (accounting for 8% of cases), commonly due to calculi, catheter blockage, or prostatic enlargement, potentially leading to anuria (<100ml/24 hours).
Acute Tubular Necrosis (ATN)
The most common hospital-acquired intrarenal AKI, characterized by tubular cell injury and destruction caused by prolonged renal ischemia or direct concentration of nephrotoxins.
Nephrotoxic ATN
Tubular cell necrosis caused by toxic agents, most commonly aminoglycosides (Amikacin, Tobramycin), Vancomycin, Zosyn (Piperacillin/Tazobactam), and iodinated radiocontrast dyes.
Onset Phase (ATN)
The initial period of ATN lasting hours to days from the initial insult until cellular injury occurs, during which renal blood flow and GFR decrease while ischemic damage evolves.
Oliguric/Anuric Phase (ATN)
The second phase of ATN where necrotic cellular debris obstructs renal tubules; characterized by muddy brown urine casts, fluid overload (elevated CVP and pulmonary artery wedge pressure), metabolic acidosis, hyperkalemia, hyponatremia, hyperphosphatemia, and hypocalcemia.
Diuretic Phase (ATN)
The third phase of ATN characterized by an increasing GFR and polyuria (2 to 4L/day), presenting risks of hypotension, declining intravascular pressures, hypokalemia, and hypernatremia.
Recovery Phase (ATN)
The final stage of ATN wherein urine output increases and kidney function slowly returns to normal or near normal over 1 to 2years; approximately 62% of surviving patients regain normal renal function, 33% develop chronic renal insufficiency (CRI), and 5% require lifelong dialysis.
Hyperkalemia
A serum potassium level >6.0mEq/L, commonly occurring in the oliguric phase of ATN; manifests clinically with muscle weakness, flaccid paralysis, nausea, peaked T-waves, prolonged PR interval, widening QRS, ventricular fibrillation, or asystole.

Peaked T-Waves
An electrocardiographic manifestation classically caused by severe hyperkalemia (K+>6.0mEq/L) that can precede lethal cardiac dysrhythmias.
Hypokalemia
A serum potassium level <3.5mEq/L, typically occurring during the diuretic phase of ATN; manifests with depressed ST segments, flat or inverted T-waves, cardiac dysrhythmias, cardiac arrest, and hypotension.

Flat T-Waves
An electrocardiographic finding indicative of hypokalemia (K+<3.5mEq/L), accompanied by ST-segment depression and an increased risk of lethal dysrhythmias.
Hyponatremia
A serum sodium level <135mEq/L, indicative of relative over-hydration or water retention; clinical findings include weakness, lethargy, headache, confusion, tremors, convulsions, seizures, and respiratory arrest related to fluid overload.
Hypernatremia
A serum sodium level >145mEq/L, indicative of dehydration; clinical findings include tachycardia, hypotension, muscle irritability, convulsions, restlessness, agitation, and decreased level of consciousness.
Hypocalcemia
A serum calcium level <8.6mg/dl, characterized by decreased cardiac output, hypotension, prolonged QT interval, bleeding tendencies, muscle spasms, Chvostek's sign, and Trousseau's sign.
Chvostek's Sign
An assessment finding for hypocalcemia consisting of involuntary facial muscle spasms elicited by tapping the facial nerve over the cheek.
Trousseau's Sign
An assessment finding for hypocalcemia consisting of carpopedal finger spasm and contraction elicited by inflating a blood pressure cuff above systolic pressure on the arm.
Hypercalcemia
A serum calcium level >10.2mg/dl, presenting with weakness, muscle flaccidity, bone pain, drowsiness, shortened QT interval, and heart blocks; treated with dietary modification, calcitonin, and diuretics.
Hyperphosphatemia
A serum phosphorus level >4.5mg/dl, typically seen in the oliguric phase of renal failure; presents with hyperreflexia, flaccid paralysis, and severe pruritus secondary to calcium-phosphate crystal deposition.
Hypophosphatemia
A serum phosphorus level <2.7mg/dl, caused by phosphate binders, alcoholism, or starvation; leads to muscle weakness (affecting respiratory function), tissue hypoxia, decreased reflexes, and bone pain.
Hypomagnesemia
A serum magnesium level <1.3mEq/L, leading to secondary hypokalemia and hypocalcemia, premature ventricular contractions (PVCs), and lethal dysrhythmias (ventricular tachycardia and ventricular fibrillation); magnesium must be replaced prior to potassium.
Renal Metabolic Acidosis
An acid/base disturbance in AKI resulting from impaired proximal tubular resorption of bicarbonate and impaired distal excretion of hydrogen ions; the resulting intracellular hydrogen movement drives potassium out of cells, exacerbating hyperkalemia.
Dialyzer
An artificial kidney cartridge containing hollow, semipermeable fibers through which blood circulates while being bathed in dialysate to remove wastes, toxins, and excess fluid by osmosis and diffusion.

Ultrafiltration
The physical removal of fluid during renal replacement therapy accomplished by applying positive hydrostatic pressure to blood and negative hydrostatic pressure to the dialysate bath, pulling excess fluid across the semipermeable membrane.

Vascular Dialysis Catheter
A dual-lumen or multi-lumen central venous access device inserted for acute circulation access to provide emergent hemodialysis or continuous renal replacement therapy.
Arteriovenous (AV) Fistula and Graft
Permanent vascular access structures created surgically in the forearm (e.g., anastomosis of the radial artery and cephalic vein or interposition of a synthetic graft) used for chronic hemodialysis access.

Peritoneal Dialysis
A form of renal replacement therapy using the patient's peritoneal membrane as the semipermeable barrier, where sterile dialysate is infused into the peritoneal cavity via a cuffed silicone catheter and subsequently drained.

Continuous Renal Replacement Therapy (CRRT)
A continuous mode of dialysis (e.g., SCUF, CVVH) that filters smaller blood volumes slowly over 12hours to several days, maintaining hemodynamic stability in critically ill, hypotensive patients unable to tolerate hemodialysis.
Capillary Leak Syndrome
Also known as third spacing; a phenomenon where fluid shifts from the intravascular space into the interstitial space due to increased capillary permeability or decreased plasma oncotic pressure.
Loss Phase (Capillary Leak Syndrome)
The initial stage of third spacing where fluid escapes into the interstitial space, producing hypovolemia, edema, decreased CVP and wedge pressures, hypotension, tachycardia, and elevated serum osmolality.
Reabsorption Phase (Capillary Leak Syndrome)
The second phase of third spacing wherein fluid shifts back from the interstitium into the intravascular space, placing the patient at risk for vascular fluid overload, pulmonary crackles, JVD, and elevated CVP.
Antidiuretic Hormone (ADH)
A hormone produced in the hypothalamus and secreted by the posterior pituitary that functions as the primary regulator of extracellular volume by acting on renal distal tubules and collecting ducts to promote water reabsorption.
Syndrome of Inappropriate Antidiuretic Hormone (SIADH)
A clinical condition characterized by continuous, excessive secretion of ADH regardless of serum osmolality, resulting in increased renal water retention, total body water expansion, concentrated hyperosmolar urine, and dilutional hyponatremia.
Central Pontine Myelinolysis
A severe neurological complication caused by overly rapid correction of severe hyponatremia in SIADH; prevented by ensuring serum sodium replacement does not exceed 1 to 2mEq/L/hour.
Demeclocycline
An antibiotic utilized in the pharmacological management of SIADH for its therapeutic side effect of diminishing renal tubule affinity for ADH, thereby promoting free water diuresis.
Diabetes Insipidus (DI)
A water balance disorder caused by a deficiency of ADH or renal resistance to ADH, manifesting with severe polyuria (3 to 20L/day), low urine specific gravity, polydipsia, high serum osmolality, and dehydration.
Central Diabetes Insipidus
A subtype of DI caused by posterior pituitary failure to secrete ADH, commonly triggered by head trauma, neurosurgery, or increased intracranial pressure (ICP); treated with Vasopressin or Desmopressin (DDAVP).
Nephrogenic Diabetes Insipidus
A subtype of DI characterized by renal tubular insensitivity or unresponsiveness to circulating ADH; managed pharmacologically with Hydrochlorothiazide (HCTZ) to enhance proximal tubule sodium and water reabsorption.